Loading organizations...
§ Private Profile · Miami, FL, USA
Neocis is a technology company.
I am unable to fetch the content from Neocis's official website due to a "Too Many Requests" error. This prevents me from conducting thorough research and gathering the specific details required to construct the company profile according to your instructions. Without access to the full webpage content, I cannot accurately describe what they build, their origin story, or their customer base and vision. Therefore, I cannot complete the company profile at this time.
Neocis has raised $232.0M across 6 funding rounds.
Neocis has raised $232.0M in total across 6 funding rounds.
Neocis is a Miami-based medical technology company pioneering robotic-assisted systems for dental implant surgery. Its flagship product, Yomi, is the first and only U.S. FDA-cleared robotic platform for this purpose, now advanced with the Yomi S system featuring AI-powered YomiPlan software for precise planning, navigation, and execution.[1][2][3][5][6][7] Neocis serves dental surgeons and practices, solving key challenges in implant procedures like inaccuracy, invasiveness, and inefficiency by enabling minimally invasive, flapless surgeries that reduce recovery time, highlight vital structures (e.g., nerves), and support same-day implants—all operable by a single practitioner via foot pedal and touchscreen.[1][2][3] The company has placed nearly 100,000 osteotomies, with customers reporting average implant volume growth post-installation, driving practice expansion and better patient outcomes.[1][7]
Neocis was founded in 2009 in Miami, Florida, by Alon Mozes, PhD (current CEO) and Juan Salcedo, both principal engineers with prior experience at Mako Surgical developing the RIO robotic system for orthopedic surgery.[6][8] Drawing from this robotics expertise, they identified a need to bring similar precision to dentistry, where manual implants often face variability and risks; their idea emerged from advancing minimally invasive techniques amid growing demand for reliable tooth replacement.[4][6][8] Early traction came with a successful 2016 clinical study leading to FDA clearance for the original Yomi by year-end, marking it as the first commercially available robot-assisted dental surgery system in the U.S.; Neocis then partnered with pioneer surgeons to establish it as a standard.[6][7]
Neocis rides the wave of AI-robotics convergence in precision medicine, particularly in dentistry's shift toward minimally invasive, data-driven procedures amid aging populations and rising implant demand (e.g., for crowns/bridges post-tooth loss).[1][4][8] Timing aligns with FDA approvals for advanced systems like Yomi S (November 2025), capitalizing on post-pandemic tele-dentistry growth and clinician shortages by empowering general practices over specialists.[2][3] Market forces favoring Neocis include falling robotics costs, AI automation (e.g., preoperative tasks), and investor interest from medtech giants, positioning it to influence ecosystem-wide adoption—partnering with dental schools for training and integrating with workflows to elevate standards, much like Intuitive Surgical did for general robotics.[1][6][7][9]
Neocis is poised to dominate dental robotics with Yomi S accelerating adoption toward 100,000+ osteotomies, expanding to more procedures via AI enhancements and global reach. Trends like AI planning ubiquity, single-practitioner scalability, and patient-centric visuals will shape its path, potentially evolving influence from niche innovator to industry standard-setter—humanizing implants as life-changing "teeth" while boosting practices amid robotics democratization. This builds on its pioneer status, transforming surgery from art to engineered precision.[1][4][7]
Neocis has raised $232.0M in total across 6 funding rounds.
Neocis's investors include Soojung Kim, Mohamed (Sid) Siddeek, Oliver Keown, Intuitive Ventures, Alumni Ventures, Amplo, Cincy Tech, IA Ventures, Lux Capital, Maveron, Mithril Capital Management, Outsized Ventures.
Neocis has raised $232.0M across 6 funding rounds. Most recently, it raised $20.0M Other Equity in January 2024.